Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications
Reviva Pharmaceuticals announced that its CEO, Laxminarayan Bhat, will participate in an A.G.P.-hosted fireside chat to discuss the clinical developments and upcoming milestones for brilaroxazine, a promising drug candidate targeting schizophrenia and other neuropsychiatric and inflammatory diseases. Positive Phase 3 data and orphan drug designatio…